Table 2.
Cost and population assessment.
| Parameters | US value (range) | China value (range) | Distribution |
|---|---|---|---|
| Drug cost, $/cycle | |||
| Enfortumab vedotin | 24,534 (19,627–29,441) 17 | 18,827 (15,062–22,592) 19 | Gamma |
| Pembrolizumab | 11,282 (9026–13,538) 17 | 560 (448–672) 20 | Gamma |
| Chemotherapy | 99 (79–119) 17 | 41 (33–49) 20 | Gamma |
| Paclitaxel | 38 (30–46) 17 | 93 (74–112) 20 | Gamma |
| Cost of AEs | |||
| EV + P | 1375 (1100–1650) 16 | 5 (4–6) 16 | Gamma |
| Chemotherapy | 8713 (6970–10,456)13,14,16 | 693 (554–832)13,14,16 | Gamma |
| Administration per cycle | 209 (167–251) 16 | 14 (11–17) 16 | Gamma |
| PD-L1 tests per patient | 476 (381–571) 21 | 137 (110–164) 21 | Gamma |
| Tumor imaging per cycle | 942 (754–1130) 21 | 143 (114–172) 21 | Gamma |
| Best supportive care per cycle | 1374 (1099–1649) 16 | 711 (569–853) 16 | Gamma |
| Terminal care per patient | 6246 (4997–7495) 22 | 1761 (1409–2113) 21 | Gamma |
| Body weight, kg | 70 (35–140) 13 | 65 (33–130) 14 | Uniform |
| Body surface area, meters 2 | 1.840 (1.472–2.208) 13 | 1.720 (1.376–2.064) 14 | Uniform |
| Discount rate | 0.030 (0–0.050) 14 | 0.05 (0–0.080) 14 | Uniform |
AEs, adverse events; EV + P, enfortumab vedotin plus pembrolizumab; PD-L1, programmed cell death ligand-1.